To test whether the reductions in endogenous DNase I levels could be offset using exogenous DNase I to alleviate clinical endpoints of disease, anti-MPO GN mice were given twice daily injections of human DNase I for 4 days. The gene discussed is MPO; the disease is ganglioneuroma.